A review of the management of the male breast carcinoma based on an analysis of 420 treated cases
A review of the management of the male breast carcinoma based on an analysis of 420 treated cases
复制标题
DOI：
10.1016/s0960-9776(96)90058-2
复制
发表时间：
1996-06-01
期刊：
影响因子：
3.9
通讯作者：
Cramer, A
中科院分区：
文献类型：
--
作者：
Ribeiro, GG;Swindell, R;Cramer, A
1941年至1991年间，英国曼彻斯特克里斯蒂医院登记了总共420例被诊断为男性乳腺癌（MBC）的病例。治疗的介绍和结果以及对世界文献的回顾构成了 MBC 管理建议的基础。主要治疗最常见的是简单的乳房切除术，然后进行放射治疗。 80% 到 100% 的肿瘤是激素受体阳性。他莫昔芬被推荐作为晚期/复发性疾病的首选药物。使用 CMF 方案的化疗在 22 名接受治疗的患者中产生了 36% 的完全或部分缓解。 39 名淋巴结阳性患者在初次治疗后接受他莫昔芬辅助治疗的早期结果表明，与“历史”对照相比，精算生存率和无病生存率显着改善。
Between 1941 and 1991, a total of 420 cases, diagnosed as having male breast carcinoma (MBC), were registered at The Christie Hospital, Manchester, UK. The presentation and results of treatment, together with a review of the world literature, form the basis of suggestions for the management of MBC. Primary treatment most commonly involves a simple mastectomy followed by radiotherapy. Between 80% and 100% of tumours are hormone-receptor positive. Tamoxifen is recommended as the drug of choice for advanced/recurrent disease. Chemotherapy, using the CMF regimen produced a 36% complete or partial response in 22 treated patients. Early results in 39 node-positive patients given adjuvant tamoxifen following primary treatment, suggest significant improvement in actuarial and disease-free survival compared to 'historical' controls.